REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Rhea-AI Summary
REGENXBIO (RGNX) has announced upcoming presentations of new interim biomarker data from their Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a treatment for Duchenne muscular dystrophy. The data will be presented at the 2025 MDA Clinical & Scientific Conference in Dallas from March 16-19, 2025.
Two presentations are scheduled: An interim clinical data presentation by Dr. Carolina Tesi Rocha from Stanford School of Medicine on March 19, and a pre-clinical research presentation on microdystrophin by Dr. Steven Foltz, Senior Scientist at REGENXBIO. Both presentations will be made available on REGENXBIO's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RGNX declined 5.21%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)
Session: Clinical Trials
Date/Time: Wednesday, March 19, 2025; 8:15 a.m. CT
Presenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health
Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)
Session: Pre-Clinical Research
Presenter: Steven Foltz, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
The presentations will be available in the Publications section of REGENXBIO's website.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--scientific-conference-302396530.html
SOURCE REGENXBIO Inc.
FAQ
What new data will RGNX present at the 2025 MDA Conference?
When and where will RGNX present their RGX-202 clinical trial results?
Who will present the RGNX clinical trial data at the 2025 MDA Conference?
What is the focus of RGNX's pre-clinical research presentation at MDA 2025?
